Document:

EXHIBIT 10.2

 

 

CONFIDENTIALITY, NONCOMPETITION AND 

NONSOLICITATION AGREEMENT

(Jacob L. Singleton)

 

This Confidentiality, Noncompetition and Nonsolicitation
Agreement (“Agreement”) is effective as of November 6, 2018 (the “Effective Date”) by The
Joint Corp., a Delaware corporation (the “Joint”), and Jacob L. Singleton (“Executive”).

 

Background

 

This Agreement is being entered into concurrently
with and as condition of a Letter Agreement with an Effective Date of November 6, 2018, between The Joint and Executive pertaining
to the terms and conditions of Executive’s employment with The Joint.

 

Now, therefore, in consideration of their mutual
promises and intending to be legally bound, the parties agree as follows:

 

1.       Confidentiality
Covenant.

 

(a)       During
Executive’s employment by the Joint and continuing indefinitely following the termination of Executive’s employment,
regardless of the reason for or circumstances of Executive’s termination, Executive shall treat all Confidential Information
as secret and confidential (Executive’s “Confidentiality Covenant”).

 

(b)       Executive
shall not under any circumstances directly or indirectly (i) disclose any Confidential Information to a third party (except as
required in the normal course of Executive’s duties or by a court order or as expressly authorized by the Joint’s Board
of Directors) or (ii) use any Confidential Information for Executive’s own account.

 

(c)       All
correspondence, files, records, documents, memoranda, reports and other items in whatever form or medium containing or reflecting
Confidential Information, whether prepared by Executive or otherwise coming into Executive’s possession, shall remain the
Joint’s exclusive property. Upon the termination of Executive’s employment, or at any other time that the Joint requests,
Executive shall promptly turn over to the Joint all written or tangible Confidential Information that may be in Executive’s
possession or control (including all copies and summaries and notes derived from Confidential Information).

 

2.       Nonsolicitation
and Noncompetition Covenant.

 

(a)       Regardless
of the reason for or circumstances of Executive’s termination, during Executive’s employment and for a period of 24
months beginning on the date of termination of Executive’s employment (the “Covenant Period”), Executive
shall not directly or indirectly do any of the following (Executive’s “Nonsolicitation and Noncompetition Covenant”):

 

(i)       solicit
for a Competing Business any customer or account of the Joint that Executive had dealings with or supervisory responsibility for,
or had access to Confidential Information relating to, during the 24-month period ending on the date of termination of Executive’s
employment; or

 

(ii)       solicit
for employment or hire away any employee of the Joint who was a full-time or part-time employee of the Joint at any time during
the 12-month period ending on the date of termination of Executive’s employment, regardless of whether the employee is or
was employed on an “at will” basis or pursuant to a written agreement; or

 

    

    

    

 

(iii)       directly
or indirectly engage in, accept employment with, or have a financial or other interest in any Competing Business.

 

(b)       The
duration of the Covenant Period shall be extended by a length of time equal to (i) the period during which Executive is in violation
of Executive’s Nonsolicitation and Noncompetition Covenant and (ii) without duplication, any period during which litigation
that the Joint institutes to enforce Executive’s Nonsolicitation and Noncompetition Covenant is pending (to the extent that
Executive is in violation of Executive’s Nonsolicitation and Noncompetition Covenant during this period). In no event, however,
shall any such extension of the Covenant Period exceed 18 months.

 

(c)       Executive’s
Nonsolicitation and Noncompetition Covenant shall apply to Executive regardless of the capacity in which Executive is acting, that
is, whether as an employee, sole proprietor, partner, joint venturer, limited liability company manager or member, shareholder,
director, consultant, adviser, principal, agent, lender, seller, buyer, supplier, vendor or in any other capacity or role.

 

(d)       Executive’s
Nonsolicitation and Noncompetition Covenant shall not be violated, however, by reason of Executive’s ownership of less than
2% of the outstanding shares of any publicly-traded corporation or other entity.

 

3.       Enforcement.

 

(a)       Executive
agrees that Executive’s violation of his Confidentiality Covenant or his Nonsolicitation and Noncompetition Covenant (Executive’s
“Covenants”) would cause irreparable harm to the Joint for which money damages alone would be both difficult
to determine and inadequate to compensate the Joint for its injury. Executive accordingly agrees that if Executive violates either
of his Covenants, the Joint shall be entitled to obtain a temporary restraining order and a preliminary and permanent injunction
to prevent Executive’s continued violation, without the necessity of proving actual damages or posting any bond or other
security.

 

(b)       This
right to injunctive relief shall be in addition to any other remedies to which the Joint may be entitled. The prevailing party
shall pay the other party’s reasonable attorneys’ fees and court costs in prosecuting or defending such lawsuit.

 

(c)       Executive
agrees that if the court in which the Joint seeks injunctive relief, or otherwise seeks to enforce any provision of this Agreement,
determines that either of Executive’s Covenants are too broad in scope or geographical area or too long in duration to be
valid and enforceable, the scope, area or duration may be reduced to limits that the court considers reasonable and, as so reduced,
the Executive’s Covenant may be enforced against Executive.

 

4.       Works.
Executive acknowledges that all Works conceived of by Executive (either alone or with others)
during Executive’s employment by the Joint shall be the Joint’s sole and exclusive property, and Executive irrevocably
assigns to the Joint all of Executive’s rights, if any, in respect of any such Invention. This assignment shall not apply
in respect of any Works for which no equipment, supplies, facilities or Confidential Information of the Joint was used and which
was developed entirely on Executive’s own time, unless (i) the Works relates to the Joint’s business or its actual
or demonstrably anticipated research or development or (ii) the Works result from any work performed for the Joint by Executive.

 

    

    

    

 

5.       Notices.
Any notice or demand under this Agreement shall be effective only if it is in writing and is delivered in person or sent by certified
or registered mail or overnight courier service. Any notice to the Joint shall be delivered or sent to it at its principal offices,
and any notice to Executive shall be sent to him at his home address as shown the Joint’s payroll records. A party may change
his or its address for purposes of this Agreement by giving notice of the change to the other party in accordance with this Paragraph.

 

6.       Amendment.
No amendment of this Agreement shall be effective unless it is in writing, makes specific reference to this Agreement and is signed
by both parties.

 

7.       Governing
Law. This Agreement and any dispute arising from or in relation to this Agreement are governed
by, and interpreted and enforced in accordance with, the laws of the State of Arizona.

 

8.       Binding
Effect. This Agreement shall be binding on, and shall inure to the benefit of, the parties
and their respective heirs, legal representatives, successors and assigns. In witness, the parties have signed this Agreement.

 

	The Joint Corp.	 	 	 
	 	 	 	 	 
	By	/s/ Peter Holt	 	/s/ Jacob L. Singleton	 
	Peter Holt, President and Chief Executive Officer	 	Jacob L. Singleton	 
	 	 	 	 	 

 

    

    

    

 

Definitions

 

Business means a person, proprietorship,
partnership, joint venture, limited liability company, corporation, enterprise or other entity, whether proprietary or not-for-profit
in nature.

 

Competing Business means a Business that
engages in the business of providing chiropractic services, directly or through related entities, including but not limited to
franchise holders, from or at any location in a Restricted Area.

 

Confidential Information means any information
relating to the Joint or their business (regardless of who prepared the information), including: trade secrets; financial information
and financial projections; marketing plans; vendor and customer information; sales and revenue information; product information;
and technology and know-how.

 

The term “Confidential Information”
does not include information that: (i) is or becomes generally available to the public other than as a result of a disclosure by
Executive in violation of this Agreement; or (ii) becomes available to Executive on a non-confidential basis from a source other
than the Joint (provided, in case (ii), that the source of the information was not known to be bound by a confidentiality agreement
or other contractual, legal or fiduciary obligation of confidentiality in respect of the information); or (iii) is communicated
in response to a valid order by a court or other governmental body, as otherwise required by law, or as necessary to establish
the rights of Executive under this Agreement, provided however that, if reasonably possible, Executive shall give the Joint written
notice of such prior to any disclosure so that the Joint may seek a protective order or other similar remedy.

 

Person means an individual, partnership,
corporation, limited liability company, association, trust, unincorporated organization, or other entity.

 

Restricted Area means anywhere within
a radius of 100 miles of any location from or at which the Joint directly, or indirectly through one or more subsidiaries or franchises,
engaged in the business of providing chiropractic services on the date of termination of Employee’s employment.

 

Works means any invention, discovery,
concept, idea, work of authorship, method, technique, process, formula or computer program, whether or not patentable, reduced
to practice or copyrightable.akao-ex101_276.htm

Exhibit 10.1

 

Amendment Two (2) 

to the 

Collaborative Development and Commercialization Agreement 

 

This Amendment 2 (“Amendment”), effective upon the date it is signed by both Parties (“Effective Date”), is by and between Microgenics and Achaogen and issued pursuant to the Collaborative Development and Commercialization Agreement (“Agreement”) dated April 26, 2016 and amended November 29, 2017. The defined terms referenced herein retain their meaning as defined in the Agreement. All amended language in this Amendment has been bolded for ease of reference. 

 

The Parties wish to amend the Agreement as stated below and hereby agree to the following terms:

 

	
1.
	
Section 3.5 Filings shall be deleted in its entirety and replaced with the following: 

 

Filings.  On a country-by-country basis, a Regulatory Approval from the applicable Regulatory Authority(ies) is required for the Assay prior to launch in such country. Upon Achaogen’s request, Microgenics shall reasonably cooperate with Achaogen with respect to any regulatory filings, submissions, or correspondence made by Achaogen related to Plazomicin in any country in the Territory, including promptly providing data, information and advice regarding the Assay, including the manufacture (including any recall information) and use thereof. This Agreement generally assumes that there is a current 510(k) pathway for obtaining Regulatory Approval for the Assay; provided, that, if a PMA pathway is required, the Parties acknowledge and agree that [***] reviewed by the Parties and may need to be adjusted to the extent agreed upon between the Parties and subject to the proviso in the foregoing sentence. For the avoidance of doubt, Achaogen shall have sole right to control any such regulatory filings, submissions, correspondence or other matters related to Plazomicin including any joint submissions or filings, but not [***], and to communicate with Regulatory Authorities related thereto.  No later than [***] (or such later date as otherwise agreed to by the Parties), the Parties shall enter into an agreement setting forth the Parties respective responsibilities for adverse event and complaint reporting, the exchange of safety data and, to the extent agreed by the Parties to be appropriate and relevant, recall matters.

 

	
2.
	
Section 7.1 shall be deleted in its entirety and replaced with the following:

 

	
 
	
7.1
	
Development Payments.  In consideration of the development efforts of Microgenics under the Research Program, Achaogen shall pay to Microgenics the following one-time payments upon the occurrence of the corresponding events:  

 

	
 
	
(a)
	
USD $[***] upon the successful completion of Phase 0: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for Phase 0;

 

	
 
	
(b)
	
USD $[***] upon the successful completion of Phase 1: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for Phase 1;

 

 

				
	
 

	
 
	
 
	
 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

Confidential Treatment Requested by Achaogen, Inc.

 

	
 
	
(c)
	
USD $[***] upon the successful completion of Phase 2: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for Phase 2; 

 

	
 
	
(d)
	
USD $[***] upon the successful completion of Phase 3: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for Phase 3;

 

	
 
	
(e)
	
USD $[***] upon the successful completion of the first milestone of Phase 4:  [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the first milestone of Phase 4;

 

An additional USD $[***] upon the successful completion of the first milestone of Phase 4:  [***] of the Project Plan, [***].

 

	
 
	
(f)
	
USD $[***] upon the successful completion of the second milestone of Phase 4: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the second milestone of Phase 4;

 

	
 
	
 (g)
	
USD $[***] upon the successful completion of the third milestone of Phase 4: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the third milestone of Phase 4;

 

An additional USD $[***] upon the successful completion of the third milestone of Phase 4; [***] of the Project Plan, [***], and [***].  

 

	
 
	
(h)
	
[***], USD $[***] upon the successful completion of the fourth milestone of Phase 4: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the fourth milestone of Phase 4;

 

	
 
	
(i)
	
USD $[***] upon the successful completion of the first milestone of Phase 5: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the first milestone of Phase 5;

 

	
 
	
(j)
	
USD $[***] upon the successful completion of the second milestone of Phase 5: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the second milestone of Phase 5;

 

	
 
	
(k)
	
[***]; and

 

	
 
	
(l)
	
[***] and assuming [***], USD $[***] upon [***]; provided, however, this amount [***].

 

	
 
	
(m)
	
[***].

Page 2 of 5

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Achaogen, Inc.

 

 

	
 
	
(n)
	
USD $[***] for development of [***].

 

7.1.1 In kind services. In consideration for the development efforts of Microgenics under the Research Program, Achaogen shall arrange and pay for the following work [***]:

 

	
 
	
(a)
	
Development of [***] under Phase 4 Milestone 3, will be arranged for at Achaogen’s expense. 

	
 
	
•
	
[***]. 

	
 
	
•
	
Microgenics will [***].

	
 
	
 (b)
	
Supply of [***] will be provided [***].

 

Thereafter, no additional payments shall be due and payable to Microgenics by Achaogen for any Assay [***].

 

	
3.
	
Exhibit A shall be deleted in its entirety and replaced with the attached Exhibit A-1.

 

	
4.
	
Exhibit F-1 shall be deleted in its entirety and replaced with the attached Exhibit F-2.

Other than as amended herein, the Agreement remains in full force and effect. 

 

[Signatures to follow on next page.]

IN WITNESS WHEREOF, the parties hereto have executed this Amendment on the date(s) set forth below and it will be effective as of the last signature date below.

 

MICROGENICS CORPORATIONACHAOGEN, INC.

 

By: /s/ [***]By: /s/ [***]

 

Name: [***] Name: [***]

Title: [***]Title: [***]

 

Page 3 of 5

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Achaogen, Inc.

 

Exhibit A – 1  

Achaogen Materials

 

 

 

			
	
Achaogen Materials
	
Estimated Amount
	
Estimated Phase Required

	
[***] 
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

 

	
 
	
(1)
	
[***]

	
 
	
*
	
[***]

	
 
	
**
	
[***]

 

 

Page 4 of 5

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Achaogen, Inc.

 

Exhibit F – 2

Project Plan Timeline and Deliverables

 

					
	
Plazomicin TDM Immunoassay Development Project Plan Timeline and Deliverables

	
Deliverables
	
Start
	
End
	
Duration (M)

	
Phase 0
	
[***]
	
[***]
	
[***]
	
[***]

	
•[***]

	
•[***]

	
Phase 1 
	
[***] 
	
[***]
	
[***]
	
[***]

	
•[***]

	
•[***]

	
Phase 2 
	
[***]
	
[***]
	
[***]
	
[***]

	
•[***]

	
•[***]

	
Phase 3 
	
[***]
	
[***]
	
[***]
	
[***]

	
•[***]

	
•[***]

	
Phase 4 
	
[***]
	
[***]
	
[***]
	
[***]

	
Milestone 1: [***]
	
[***]
	
[***]
	
[***]

	
•[***]  

	
Milestone 2: [***]
	
[***]
	
[***]
	
[***]

	
•[***]

	
Milestone 3: [***]
	
[***]
	
[***]
	
[***]

	
•[***]

	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
•[***] 

	
Phase 5
	
[***]
	
[***]
	
 
	
[***]

	
Milestone 1: [***]
	
[***]
	
[***]
	
[***]

	
[***]

	
Milestone 2: [***]
	
[***]
	
[***]
	
[***]

	
•[***]

 

 

Page 5 of 5

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]